Skip to main content

Knowledge center

All resources

adenoviral vector product from bench to clinic

Taking your adenoviral vector product from R&D to the clinic

| Blog, Featured, Viral vaccines, Viral vectors | No Comments
Adenoviruses have been shown to be very effective vehicles for delivering genetic material to cells and are therefore in demand to develop gene therapies and vaccine products. The road from…
Adenovirus vectors gene therapy and vaccine development

Adenovirus vectors: cutting edge delivery vehicles for gene therapy and vaccine development

| Blog, Featured, Viral vaccines, Viral vectors | No Comments
Adenovirus (Ad) vectors are used to develop gene therapy products and vaccines. Decades of research stand behind these vectors which have gone through several iterations and improvements to make them…
Past and current challenges of adenoviral vector platforms

Adenoviral vector platform: past and current challenges

| Blog, Featured, Viral vaccines, Viral vectors | No Comments
Adenoviruses have been explored for gene therapy purposes for many decades. They are DNA viruses, with a double-stranded DNA genome of around 26-45 kilobases. Adenoviruses have been isolated from a…

Solving challenges in manufacturing viral vector based ATMPs

| Blog, Viral vectors | No Comments
Written by expert: Kai, Technical Lead The obstacles of viral vector production Over the last decade, the scientific community has witnessed several breakthroughs in the field of gene therapy and…
Planning a drug development strategy

How to devise a drug development plan that actually works

| Blog | No Comments
A well-crafted product development plan (PDP) can play a pivotal role in the development and commercialization of a new drug product, but creating one takes time, commitment, and a lot…
How to turn an innovative drug candidate into a commercial success: the product development plan explained

How to turn an innovative drug candidate into a commercial success – the product development plan explained

| Blog | No Comments
Without doubt, biotech startups and smaller pharmaceutical companies have become the major drivers of innovation in the pharmaceutical industry. In 2020, 63% of approved new therapeutic drugs in Europe and…
Finding your niche in the funding ecosystem for biotech startups

Biotech startups – understanding the ecosystem for success

| Blog | No Comments
Biotechnology is in the midst of a great era of innovation, with an ever-expanding toolbox of drug modalities spawning development of exciting new vaccines, medicines and therapies. Today’s ecosystem for…
Vaccine development

How the Netherlands became a key player for vaccine development

| Article | No Comments
The Netherlands has a long history in the life sciences industry. Especially in the field of vaccine development and manufacturing, this small country has always played a significant role. Lately,…
Interview on future of vector vaccines

Interview Menzo Havenga on Future of Vector Vaccines

| Article | No Comments
Now that the mRNA-based SARS-CoV-2 vaccines turn out to be successful, is there still a future for vector-based vaccines? "Absolutely", says expert Menzo Havenga (CEO, Batavia Biosciences). In an interview…
Viral vector Center of excellence CDMO

What type of CDMO is the right fit for you? Vendor versus center of excellence

| Blog | No Comments
When it comes to outsourcing, there is often confusion about the type of partner that is most appropriate for a project. In our previous article, we discussed the difference between…
Partnering for success with a CDMO for viral vectors

How to work with a CDMO for viral vectors: 5 steps to success

| Blog | No Comments
Viral vector technologies are at the heart of many promising new therapies, such as vaccines, gene therapies, immune-oncology therapies and other advanced therapy medicinal products (ATMPs). In this rapidly evolving…
Batavia provides specialized CDMO services for viral vaccine and viral vector development, scale-up and manufacture

GMP viral vector and viral vaccine production: Is outsourcing to a CDMO the answer for your project?

| Blog | No Comments
Developing a successful viral vaccine or viral vector for use in a clinical setting is notoriously challenging. Unforeseen pitfalls and roadblocks in process development and scale-up can lead to costly…
Viral vaccine and viral vector manufacturing scale-up

Accelerating viral vector and vaccine development: beware the pitfalls of scale-up

| Blog, Viral vaccines, Viral vectors | No Comments
You’ve developed a candidate viral vaccine or viral vector product, and initial preclinical data are showing excellent efficacy. Now you’re ready to scale up for IND application and testing in…
next virus outbreak

How we prepare for the next virus outbreak

| Article | No Comments
Recently, Menzo Havenga (CEO at Batavia Biosciences) was interviewed by the online magazine named “Startup Info”. This magazine is devoted to informing its readers on the booming startup ecosystem worldwide.…

How important is matrix effect in analyzing bioprocess samples?

| Blog, Proteins antibodies | No Comments
Written by expert: Gert, Associate Director Assays The matrix effect is the effect on an analytical assay caused by all other components of the sample except the specific compound (analyte)…
TOP 10 CMOs 2020

PharmaTech Outlook interviews Menzo Havenga for its top 10 CMOs 2020 special

| Article | No Comments
For its special on the top 10 CMOs of 2020 PharmaTech Outlook has interviewed our CEO, Menzo Havenga. In the interview, Menzo elaborates some of the key technologies and expertise…
gene therapy AAV vector production

Gene therapies push AAV vector production

| Article | No Comments
Several virus types have been studied for use as viral vectors in gene therapy, including adenovirus, lentivirus, retrovirus, and adeno-associated virus (AAV). All platforms have their own advantages over one…
COVID-19 vaccine candidate

Gene therapy developers see an expanded viral toolbox

| Article | No Comments
There are still many challenges in gene therapy analytics and manufacturing according to gene therapy developers. Our Global Technical Director, Alfred Luitjens was interviewed on this topic by Genetic Engineering…
Interview on future of vector vaccines

Interview Menzo Havenga in newspaper: fight against coronavirus

| Article | No Comments
Our CEO, Menzo Havenga, has been interviewed by the local Dutch newspaper, Leidsch Dagblad. In the article, Menzo discusses Batavia's role in the fight against the coronavirus and his vision…
Fixed-bed bioreactors for viral vector manufacturing

Do fixed-bed bioreactors provide a solution to viral vector shortage?

| Blog, Viral vectors | No Comments
Written by expert: Yang, Bioprocess Scientist In 2017, the New York Times wrote an article to report the critical shortage in the global viral vector manufacturing capacity. Next to the…
Research and development biopharmaceuticals

Fairy godmother for research and development biopharmaceuticals

| Article | No Comments
This week, the New Economy placed an article on the role of Batavia Biosciences in the research and development of biopharmaceuticals. Only five percent of candidate drugs currently make it…
Cell line development for difficult to express proteins

Developing stable cell lines for difficult to express proteins: laronidase example

| Blog, Proteins antibodies | No Comments
Written by expert: Wilfried, Director of Science and Innovation For protein-based biopharmaceuticals, product yield from mammalian cell lines is a critical economic driver. Naturally, increased specific productivity – microgram product…
process intensification biomanufacturing

Need for process intensification in biomanufacturing

| Article | No Comments
“If it’s not broken, don’t fix it.” This truism is given a lot of weight in biomanufacturing, where tried-and-true methods predominate. New methods, however, are getting a hearing. They appeal…
virs manufacturing GMP

Challenges in virus-based manufacturing in GMP

| Blog, Viral vaccines | No Comments
 Written by expert: Marije, GMP Scientist Many customers want to know how much time it will take to move a candidate viral vaccine or viral vector product from bench to…
analytical assay development

Analytical assay development: go ALL the way

| Blog | No Comments
Written by expert: Gert, Associate Director Assays The truth is; the accuracy and robustness of any process under development or manufacturing outcome is only as good as the reliability of…
bioprocess intensification for vaccine production

Latest advancements in bioprocess intensification for efficient biopharmaceutical production

| Blog, Viral vaccines, Viral vectors | No Comments
Written by expert: Ahd, Director Project Management Current costs of biopharmaceutical manufacturing often prevent segments of the world’s population from accessing critical medicines. Sometimes the costs even prevent medicines from…
protein expressing cell line

Improved selection of protein-producing cell lines using a scale-down approach – a case study

| Blog, Proteins antibodies | No Comments
Written by expert: Alfred, Global Technical Sales Director The selection of stable protein producing cell lines is tedious, time consuming and capital intensive. The introduction of various high-throughput cell screening…
WVC 2022

Genetic stability studies: could process parameters change your virus?

| Blog, Viral vaccines | No Comments
Written by expert: Monika, Associate Director Viral Vector Development Despite having very limited coding capacity, most of the RNA viruses are surprisingly good at escaping the hosts immune response and withstanding…
downstream processing of viral vectors

Tackling the capacity bottleneck in downstream processing of viral vectors

| Blog, Viral vectors | No Comments
Written by expert: Evert, Associate Director DSP With the first gene therapies now being on the market, the production quantities for gene therapy vectors are increasing to satisfy the demand.…
Quality Control

In manufacturing it’s ALL about Quality Control

| Blog | No Comments
Written by expert: Caroline, Sr. Scientist Quality Control The Quality Control (QC) department performs analytical development, assay qualification, assay validation, testing on raw materials, cell substrates, virus seeds and cell…

Making Research Count

| Article | No Comments
Our CEO, Menzo Havenga has a hobby horse, a Clinical Development Board. It should ensure that high impact research will result in high quality products for patients. Currently in the…
clinical GMP manufacturing

Drivers in selecting a reliable partner for clinical GMP manufacturing

| Blog | No Comments
Written by expert: Pim, sr. GMP Scientist Clinical GMP manufacturing and release of biopharmaceutical products are two of the most sought-after outsourcing demands in life sciences. These activities are needed…
Better influenza vaccine

Nanodisc offers chance better influenza vaccine

| Article | No Comments
The Dutch newspaper, Leidsch Dagblad, published an article on the TTW-grant that the Leiden University has received to collaborate with private partners ZoBio, and Batavia Biosciences to propel SATIRN® technology, developed by…
Quality in biopharmaceutical development

Quality specialist is key in any biopharmaceutical development team

| Blog | No Comments
Written by Expert: Margreet, sr. QA specialist The ability to translate biopharmaceutical research into products is known to have a high failure rate. A staggering 75% of published preclinical data…
Zika vaccine

SIDUS® technology enables first clinical study with live attenuated Zika vaccine

| Article | No Comments
Batavia Biosciences has, with its know-how developed under the SIDUS® technology, extensive expertise in house for the production and testing of viral vector based products, like lentiviral vectors, adenoviral vectors,…
Interview Alfred Luitjens - Process Development Software

Interview with Alfred Luitjens by Biopharm

| Article | No Comments
Batavia Biosciences uses Biopharm's BioSolve as process development software. The software enables us to predict the effect of suggested process development steps on, for example the Cost of Goods, and…
increase production yield

The need to increase production yield of therapeutic proteins

| Blog, Proteins antibodies | No Comments
Written by Expert: Wilfried, Director Science & Innovation. Biopharmaceuticals are expensive due to the many years of research and development associated with the discovery, development, clinical testing, and market launch…
HPLC assays for vaccines

Novel HPLC assays allow for better biopharmaceutical development

| Blog, Viral vaccines, Viral vectors | No Comments
Written by expert: Gert, Associate Director Assays HPLC assays have been widely used to analyze small molecules for decades. Now, HPLC is gaining momentum as an important tool for analysis…
microcarrier process development

How to scale your adherent cell culture

| Blog | No Comments
Written by expert: Matthijs, Associate Director Upstream Bioprocessing Cells derived from mammalian species and cultured under artificial laboratory conditions are used to produce complex biological products. As such cells normally…
Biosimilar development - scientist

Tackling the challenges in biosimilar development

| Article | No Comments
Yield is still an area that requires significant improvement for many promising recombinant protein and antibody products. Especially in the field of biosimilars, the ability to manufacture products cost-efficiently has…
Viral vector manufacturing clinical manufacturing

SIDUS® Technology for viral vector manufacturing

| Article | No Comments
Viral vectors are highly valued in many therapeutic fields given the promise of low cost and safe manufacturing coupled with high product efficacy and an excellent safety profile. Engineered with…
Menzo Havenga - Future Biotech Outsourcing Market

The future of the biotech outsourcing market

| Blog | No Comments
Written by expert: Menzo, CEO Batavia Biosciences The current biotech outsourcing market for biopharmaceuticals encompasses about $5.5 billion annually with by far the biggest spending in early development. It is…
Batavia Biosciences Best Biotech Company

Why Batavia Biosciences is the Best Biotech Company in the Netherlands

| Article | No Comments
Batavia Biosciences was awarded Best Biotech Company of the Netherlands in the NBSA 2016. We aim to significantly contribute to ease human suffering from disease by improving the success rate in the…
adenoviral vector product from bench to clinic

Taking your adenoviral vector product from R&D to the clinic

| Blog, Featured, Viral vaccines, Viral vectors | No Comments
Adenoviruses have been shown to be very effective vehicles for delivering genetic material to cells and are therefore in demand to develop gene therapies and vaccine products. The road from…
Adenovirus vectors gene therapy and vaccine development

Adenovirus vectors: cutting edge delivery vehicles for gene therapy and vaccine development

| Blog, Featured, Viral vaccines, Viral vectors | No Comments
Adenovirus (Ad) vectors are used to develop gene therapy products and vaccines. Decades of research stand behind these vectors which have gone through several iterations and improvements to make them…
Past and current challenges of adenoviral vector platforms

Adenoviral vector platform: past and current challenges

| Blog, Featured, Viral vaccines, Viral vectors | No Comments
Adenoviruses have been explored for gene therapy purposes for many decades. They are DNA viruses, with a double-stranded DNA genome of around 26-45 kilobases. Adenoviruses have been isolated from a…

Solving challenges in manufacturing viral vector based ATMPs

| Blog, Viral vectors | No Comments
Written by expert: Kai, Technical Lead The obstacles of viral vector production Over the last decade, the scientific community has witnessed several breakthroughs in the field of gene therapy and…
Planning a drug development strategy

How to devise a drug development plan that actually works

| Blog | No Comments
A well-crafted product development plan (PDP) can play a pivotal role in the development and commercialization of a new drug product, but creating one takes time, commitment, and a lot…
How to turn an innovative drug candidate into a commercial success: the product development plan explained

How to turn an innovative drug candidate into a commercial success – the product development plan explained

| Blog | No Comments
Without doubt, biotech startups and smaller pharmaceutical companies have become the major drivers of innovation in the pharmaceutical industry. In 2020, 63% of approved new therapeutic drugs in Europe and…
Finding your niche in the funding ecosystem for biotech startups

Biotech startups – understanding the ecosystem for success

| Blog | No Comments
Biotechnology is in the midst of a great era of innovation, with an ever-expanding toolbox of drug modalities spawning development of exciting new vaccines, medicines and therapies. Today’s ecosystem for…
Viral vector Center of excellence CDMO

What type of CDMO is the right fit for you? Vendor versus center of excellence

| Blog | No Comments
When it comes to outsourcing, there is often confusion about the type of partner that is most appropriate for a project. In our previous article, we discussed the difference between…
Partnering for success with a CDMO for viral vectors

How to work with a CDMO for viral vectors: 5 steps to success

| Blog | No Comments
Viral vector technologies are at the heart of many promising new therapies, such as vaccines, gene therapies, immune-oncology therapies and other advanced therapy medicinal products (ATMPs). In this rapidly evolving…
Batavia provides specialized CDMO services for viral vaccine and viral vector development, scale-up and manufacture

GMP viral vector and viral vaccine production: Is outsourcing to a CDMO the answer for your project?

| Blog | No Comments
Developing a successful viral vaccine or viral vector for use in a clinical setting is notoriously challenging. Unforeseen pitfalls and roadblocks in process development and scale-up can lead to costly…
Viral vaccine and viral vector manufacturing scale-up

Accelerating viral vector and vaccine development: beware the pitfalls of scale-up

| Blog, Viral vaccines, Viral vectors | No Comments
You’ve developed a candidate viral vaccine or viral vector product, and initial preclinical data are showing excellent efficacy. Now you’re ready to scale up for IND application and testing in…

How important is matrix effect in analyzing bioprocess samples?

| Blog, Proteins antibodies | No Comments
Written by expert: Gert, Associate Director Assays The matrix effect is the effect on an analytical assay caused by all other components of the sample except the specific compound (analyte)…
Fixed-bed bioreactors for viral vector manufacturing

Do fixed-bed bioreactors provide a solution to viral vector shortage?

| Blog, Viral vectors | No Comments
Written by expert: Yang, Bioprocess Scientist In 2017, the New York Times wrote an article to report the critical shortage in the global viral vector manufacturing capacity. Next to the…
Cell line development for difficult to express proteins

Developing stable cell lines for difficult to express proteins: laronidase example

| Blog, Proteins antibodies | No Comments
Written by expert: Wilfried, Director of Science and Innovation For protein-based biopharmaceuticals, product yield from mammalian cell lines is a critical economic driver. Naturally, increased specific productivity – microgram product…
virs manufacturing GMP

Challenges in virus-based manufacturing in GMP

| Blog, Viral vaccines | No Comments
 Written by expert: Marije, GMP Scientist Many customers want to know how much time it will take to move a candidate viral vaccine or viral vector product from bench to…
analytical assay development

Analytical assay development: go ALL the way

| Blog | No Comments
Written by expert: Gert, Associate Director Assays The truth is; the accuracy and robustness of any process under development or manufacturing outcome is only as good as the reliability of…
bioprocess intensification for vaccine production

Latest advancements in bioprocess intensification for efficient biopharmaceutical production

| Blog, Viral vaccines, Viral vectors | No Comments
Written by expert: Ahd, Director Project Management Current costs of biopharmaceutical manufacturing often prevent segments of the world’s population from accessing critical medicines. Sometimes the costs even prevent medicines from…
protein expressing cell line

Improved selection of protein-producing cell lines using a scale-down approach – a case study

| Blog, Proteins antibodies | No Comments
Written by expert: Alfred, Global Technical Sales Director The selection of stable protein producing cell lines is tedious, time consuming and capital intensive. The introduction of various high-throughput cell screening…
WVC 2022

Genetic stability studies: could process parameters change your virus?

| Blog, Viral vaccines | No Comments
Written by expert: Monika, Associate Director Viral Vector Development Despite having very limited coding capacity, most of the RNA viruses are surprisingly good at escaping the hosts immune response and withstanding…
downstream processing of viral vectors

Tackling the capacity bottleneck in downstream processing of viral vectors

| Blog, Viral vectors | No Comments
Written by expert: Evert, Associate Director DSP With the first gene therapies now being on the market, the production quantities for gene therapy vectors are increasing to satisfy the demand.…
Quality Control

In manufacturing it’s ALL about Quality Control

| Blog | No Comments
Written by expert: Caroline, Sr. Scientist Quality Control The Quality Control (QC) department performs analytical development, assay qualification, assay validation, testing on raw materials, cell substrates, virus seeds and cell…
clinical GMP manufacturing

Drivers in selecting a reliable partner for clinical GMP manufacturing

| Blog | No Comments
Written by expert: Pim, sr. GMP Scientist Clinical GMP manufacturing and release of biopharmaceutical products are two of the most sought-after outsourcing demands in life sciences. These activities are needed…
Quality in biopharmaceutical development

Quality specialist is key in any biopharmaceutical development team

| Blog | No Comments
Written by Expert: Margreet, sr. QA specialist The ability to translate biopharmaceutical research into products is known to have a high failure rate. A staggering 75% of published preclinical data…
increase production yield

The need to increase production yield of therapeutic proteins

| Blog, Proteins antibodies | No Comments
Written by Expert: Wilfried, Director Science & Innovation. Biopharmaceuticals are expensive due to the many years of research and development associated with the discovery, development, clinical testing, and market launch…
HPLC assays for vaccines

Novel HPLC assays allow for better biopharmaceutical development

| Blog, Viral vaccines, Viral vectors | No Comments
Written by expert: Gert, Associate Director Assays HPLC assays have been widely used to analyze small molecules for decades. Now, HPLC is gaining momentum as an important tool for analysis…
microcarrier process development

How to scale your adherent cell culture

| Blog | No Comments
Written by expert: Matthijs, Associate Director Upstream Bioprocessing Cells derived from mammalian species and cultured under artificial laboratory conditions are used to produce complex biological products. As such cells normally…
Menzo Havenga - Future Biotech Outsourcing Market

The future of the biotech outsourcing market

| Blog | No Comments
Written by expert: Menzo, CEO Batavia Biosciences The current biotech outsourcing market for biopharmaceuticals encompasses about $5.5 billion annually with by far the biggest spending in early development. It is…

Adenoviral vectors for cardiovascular gene therapy applications: a clinical and industry perspective

| Featured, Scientific publication | No Comments
Adenoviruses are being explored as vectors for cardiovascular gene therapy purposes against many heritable diseases. Gene transfer vectors, based on human adenovirus serotype 5, were some of the first developed…
Modeling long-term stability rotavirus vaccine liquid formulation

Modeling long-term stability profiles of novel rotavirus vaccine in liquid formulations

| Scientific publication | No Comments
We are proud to announce a fourth publication coming from our rotavirus vaccine project, funded by the Bill & Melinda Gates Foundation. The journal Biologicals has published scientific data generated…
adenoviral vector adv-20-42-42

AdV-20-42-42, promising adenoviral vector for gene therapy and vaccine product development

| Scientific publication | No Comments
Adenoviruses are being explored as vectors for vaccines against various infectious diseases, such as COVID-19, and as vectors for gene therapy purposes against many heritable diseases. Pre-existing immune responses towards…
stable high yield expression of difficult to express proteins

Stable, high yield expression of HIV gp145

| Scientific publication | No Comments
We are proud to announce that the peer-reviewed journal Biologicals has now published our work on the high yield expression of an HIV envelope protein. Despite numerous advances in the…
Live rotavirus vaccine formulation development

Formulation development live rotavirus vaccine candidate for use low- and middle-income countries

| Scientific publication | No Comments
We are proud to announce a third publication coming from our rotavirus vaccine project, funded by the Bill & Melinda Gates Foundation. The peer-reviewed journal Human Vaccines & Immunotherapeutics has…
Stable CHO cell line development for difficult-to-express proteins

STEP® vectors for rapid generation of stable CHO cell lines for difficult-to-express proteins

| Scientific publication | No Comments
Many proteins produced in CHO cells need evaluation for their clinical and commercial potential. Traditional methods based on stable clone generation are slow and unsuitable for screening larger numbers of…
Process development for rotavirus vaccine

Process development for cost-effective, liquid rotavirus vaccine

| Scientific publication | No Comments
We are proud to announce that our recent manuscript has been accepted for publication in the journal Vaccine. The manuscript describes the development of a low-cost manufacturing process for a…
adenovirus hexon capsid

Human adenovirus hexon capsid protein mediates cell entry through CD46

| Scientific publication | No Comments
Adenoviruses are being explored as vectors for vaccines against various infectious diseases, such as COVID-19, and as vectors for gene therapy purposes against many heritable diseases. The efficacy of adenoviral…
Stable CHO cell line development for difficult-to-express proteins

Effect of formulation variables on stability of live rotavirus vaccine candidate

| Scientific publication | No Comments
We are proud to announce that the Journal of Pharmaceutical Sciences has published scientific data generated together with the University of Kansas on the stability of a novel rotavirus (RV3-BB)…
Batavia Biosciences antibody fragments e.coli

Expression system for HIV-neutralizing antibody fragments in E. coli

| Scientific publication | No Comments
Monoclonal antibodies are of paramount importance in diagnosis and treatment of human disease. Therefore, great technological progress has been made in the manufacturing of antibodies using mammalian expression hosts, substantially…
Viral vector - hematopoietic stem cells

Ex vivo expansion of hematopoietic stem cells for therapeutic purposes

| Scientific publication | No Comments
Batavia Biosciences collaborates with the group of prof. dr. Frank Staal at LUMC on developing new packaging cell lines for lentiviral vector productions for the field of gene therapy. As…
Adenovirus vector vaccine | paper Batavia Biosciences

First-in-human randomized controlled trial of adenovirus 26 vector vaccine for HIV-1

| Scientific publication | No Comments
The scientific journal PLOS ONE published an article on the first-in-human trial studying safety and effectiveness of an attenuated HIV-1 adenovirus vector vaccine by the group of Dr. Dan Barouch.…
knockout vero cell lines

Enhancing viral vaccine production using engineered knockout Vero cell lines – A second look

| Scientific publication | No Comments
The global adoption of vaccines to combat disease is hampered by the high cost of vaccine manufacturing. The work described herein follows two previous publications (van der Sanden et al.,…
Gene therapy and vaccination vector

Generation of novel candidate gene therapy and vaccination vector based on adenovirus

| Scientific publication | No Comments
The vectorization of rare human adenovirus (HAdV) types will widen our knowledge of this family and their interaction with cells, tissues and organs. In this study we focus on HAdV-56,…
Manufacturing Adenoviral vectors

Challenges in Manufacturing Adenoviral Vectors for Global Vaccine Product Deployment

| Scientific publication | No Comments
Once adenoviral vector-based vaccines are licensed for the prevention of important infectious diseases, manufacturing processes capable of reliably delivering large numbers of vaccine doses will be required. The highest burden…
vacancy technician assays / analytical development

Development of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5–based Constructs

| Scientific publication | No Comments
Recombinant vectors based on human adenovirus serotype 5 (HAdV-5) have been extensively studied in preclinical models and clinical trials over the past two decades. However, the thorough understanding of the…
Vaccine development

How the Netherlands became a key player for vaccine development

| Article | No Comments
The Netherlands has a long history in the life sciences industry. Especially in the field of vaccine development and manufacturing, this small country has always played a significant role. Lately,…
Interview on future of vector vaccines

Interview Menzo Havenga on Future of Vector Vaccines

| Article | No Comments
Now that the mRNA-based SARS-CoV-2 vaccines turn out to be successful, is there still a future for vector-based vaccines? "Absolutely", says expert Menzo Havenga (CEO, Batavia Biosciences). In an interview…
next virus outbreak

How we prepare for the next virus outbreak

| Article | No Comments
Recently, Menzo Havenga (CEO at Batavia Biosciences) was interviewed by the online magazine named “Startup Info”. This magazine is devoted to informing its readers on the booming startup ecosystem worldwide.…
TOP 10 CMOs 2020

PharmaTech Outlook interviews Menzo Havenga for its top 10 CMOs 2020 special

| Article | No Comments
For its special on the top 10 CMOs of 2020 PharmaTech Outlook has interviewed our CEO, Menzo Havenga. In the interview, Menzo elaborates some of the key technologies and expertise…
gene therapy AAV vector production

Gene therapies push AAV vector production

| Article | No Comments
Several virus types have been studied for use as viral vectors in gene therapy, including adenovirus, lentivirus, retrovirus, and adeno-associated virus (AAV). All platforms have their own advantages over one…
COVID-19 vaccine candidate

Gene therapy developers see an expanded viral toolbox

| Article | No Comments
There are still many challenges in gene therapy analytics and manufacturing according to gene therapy developers. Our Global Technical Director, Alfred Luitjens was interviewed on this topic by Genetic Engineering…
Interview on future of vector vaccines

Interview Menzo Havenga in newspaper: fight against coronavirus

| Article | No Comments
Our CEO, Menzo Havenga, has been interviewed by the local Dutch newspaper, Leidsch Dagblad. In the article, Menzo discusses Batavia's role in the fight against the coronavirus and his vision…
Research and development biopharmaceuticals

Fairy godmother for research and development biopharmaceuticals

| Article | No Comments
This week, the New Economy placed an article on the role of Batavia Biosciences in the research and development of biopharmaceuticals. Only five percent of candidate drugs currently make it…
process intensification biomanufacturing

Need for process intensification in biomanufacturing

| Article | No Comments
“If it’s not broken, don’t fix it.” This truism is given a lot of weight in biomanufacturing, where tried-and-true methods predominate. New methods, however, are getting a hearing. They appeal…

Making Research Count

| Article | No Comments
Our CEO, Menzo Havenga has a hobby horse, a Clinical Development Board. It should ensure that high impact research will result in high quality products for patients. Currently in the…
Better influenza vaccine

Nanodisc offers chance better influenza vaccine

| Article | No Comments
The Dutch newspaper, Leidsch Dagblad, published an article on the TTW-grant that the Leiden University has received to collaborate with private partners ZoBio, and Batavia Biosciences to propel SATIRN® technology, developed by…
Zika vaccine

SIDUS® technology enables first clinical study with live attenuated Zika vaccine

| Article | No Comments
Batavia Biosciences has, with its know-how developed under the SIDUS® technology, extensive expertise in house for the production and testing of viral vector based products, like lentiviral vectors, adenoviral vectors,…
Interview Alfred Luitjens - Process Development Software

Interview with Alfred Luitjens by Biopharm

| Article | No Comments
Batavia Biosciences uses Biopharm's BioSolve as process development software. The software enables us to predict the effect of suggested process development steps on, for example the Cost of Goods, and…
Biosimilar development - scientist

Tackling the challenges in biosimilar development

| Article | No Comments
Yield is still an area that requires significant improvement for many promising recombinant protein and antibody products. Especially in the field of biosimilars, the ability to manufacture products cost-efficiently has…
Viral vector manufacturing clinical manufacturing

SIDUS® Technology for viral vector manufacturing

| Article | No Comments
Viral vectors are highly valued in many therapeutic fields given the promise of low cost and safe manufacturing coupled with high product efficacy and an excellent safety profile. Engineered with…
Batavia Biosciences Best Biotech Company

Why Batavia Biosciences is the Best Biotech Company in the Netherlands

| Article | No Comments
Batavia Biosciences was awarded Best Biotech Company of the Netherlands in the NBSA 2016. We aim to significantly contribute to ease human suffering from disease by improving the success rate in the…
Design of Experiments is Biopharmaceutical Development

Design of Experiments in Biopharmaceutical Development

| Webinar | No Comments
In this webinar you will learn how to use Design of Experiments (DoE) in planning your experiments and analyzing the data obtained. We will guide you through all phases of…
STEP plasmid for Enhanced Protein Expression

STEP® Technology – Delivering High Protein Production

| Webinar | No Comments
In this webinar we will introduce STEP® and its ability to rapidly and easily generate cell lines with high protein production yields in the industrial workhorse CHO. The stability of expression and…
Nice to meet you, we are Batavia Biosciences

Nice to meet you, we are Batavia Biosciences

| Video | No Comments
We are a biopharmaceutical CDMO with expertise in viral vectors, viral vaccines, proteins and antibodies. We are not your standard CDMO - our customers regularly refer to us as their…
Batavia Biosciences, your Biopharmaceutical CDMO

Batavia Biosciences, your biopharmaceutical CDMO

| Video | No Comments
Batavia Biosciences is a biopharmaceutical CDMO with an extensive track record in viral vaccine, viral vector, protein and antibody projects. We aim to significantly contribute to ease human suffering from…